Probiotec (PBP) Stock Price, News & Analysis

Company Overview

Probiotec Limited engages in the development, manufacture, packing, distribution, and sale of prescription and over the counter pharmaceuticals, complementary medicines and consumer health products, and fast-moving consumer products in Australia and internationally. The company provides contract manufacturing services for solid dose tablets, capsules, and caplets; tablets coatings; blister packs, bottles, sachets, tubs, and tubes; liquids, creams, gels, lotions, ointments, and powders and powder blends. It is also involved in analytical and stability testing services; new product formulation and production trials, and ongoing research and development services; and packaging options for human and animal nutrition products, as well as manufactures and exports a range of nutraceuticals and functional ingredient raw materials. The company was incorporated in 1996 and is headquartered in Laverton North, Australia.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 26,253 shs
• Average Volume: N/A
• Market Capitalization: A$242.34 million
• P/E Ratio: 21.99
• Dividend Yield: 2.43%
• Price Target: N/A
• Consensus Rating: N/A

PBP Stock Analysis - Frequently Asked Questions

How were Probiotec's earnings last quarter?

Probiotec Limited (ASX:PBP) released its quarterly earnings results on Tuesday, February, 26th. The company reported $0.02 earnings per share (EPS) for the quarter. Probiotec had a net margin of 5.15% and a trailing twelve-month return on equity of 13.26%.

What other stocks do shareholders of Probiotec own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Probiotec investors own include Allied Gaming & Entertainment (AGAE), Avino Silver & Gold Mines (ASM), Academy Sports and Outdoors (ASO), Berkeley Energia (BKY), Global X Cloud Computing ETF (CLOU), VelocityShares 1x Long VSTOXX Futures ETN (EVIX) and First Trust United Kingdom AlphaDEX Fund (FKU).

Company Calendar

• Last Earnings: 2/26/2019
• Today: 7/18/2025

Industry, Sector and Symbol

• Stock Exchange: ASX
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: N/A
• Current Symbol: ASX:PBP
• CIK: N/A
• Web: www.probiotec.com.au
• Phone: 61 3 9278 7555
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): A$0.10
• Trailing P/E Ratio: 21.99
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: A$8.69 million
• Net Margins: 5.15%
• Pretax Margin: N/A
• Return on Equity: 13.26%
• Return on Assets: 5.09%

Debt

• Debt-to-Equity Ratio: 100.87
• Current Ratio: 0.81
• Quick Ratio: 1.04

Sales & Book Value

• Annual Sales: A$221.22 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 16.79
• Book Value: A$1.07 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 81,320,000
• Free Float: N/A
• Market Cap: A$242.34 million
• Optionable: Not Optionable
• Beta: 0.44